Scandinavian Prostate Cancer Patients’ Sexual Problems and Satisfaction With Their Sex Life Following Anti-Cancer Treatment

Hald, Gert Martin; Pind, Mie Dahl; Borre, Michael; Lange, Theis

doi:10.1016/j.esxm.2018.06.002

Cited by 20 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although patients who reach their baseline erectile function will not necessarily need to manage sexual satisfaction, 10,80 the erectile function score is not correlated with overall satisfaction. In the literature, several factors in addition to erectile function were found to be associated with sexual satisfaction: sexual desire, intensity of orgasm, sexual self‐esteem, age, time since diagnosis, relationship variables, and psychological variables such as depression and anxiety 80–84 . There is a significant association between depressive symptoms and erectile dysfunction, and depressive symptoms may contribute to a delay in the improvement of sexual satisfaction in patients with ED due to RARP 83,85 .…”

Section: Psychological Concernsmentioning

confidence: 99%

“…In the literature, several factors in addition to erectile function were found to be associated with sexual satisfaction: sexual desire, intensity of orgasm, sexual self-esteem, age, time since diagnosis, relationship variables, and psychological variables such as depression and anxiety. [80][81][82][83][84] There is a significant association between depressive symptoms and erectile dysfunction, and depressive symptoms may contribute to a delay in the improvement of sexual satisfaction in patients with ED due to RARP. 83,85 We must clarify whether this depressive condition may be caused by ED per se or the combination of the other sexual dysfunction symptoms.…”

Section: Psychological Concernsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of sexual function after robot‐assisted radical prostatectomy: A farewell toIIEFquestionnaire

Shiraishi

2023

Int J of Urology

View full text Add to dashboard Cite

Longevity with localized prostate cancer (PCa) has been achieved, and the contribution of robot‐assisted radical prostatectomy (RARP) to cancer control is evident. The next step to investigate in the treatment of localized PCa is improvement of the quality of life (QOL) after RARP. Erectile dysfunction has been considered a major surgical complication, and patient satisfaction after RARP has not improved despite the development of nerve preservation and penile rehabilitation. To comprehensively understand sexual dysfunction after RARP, we must investigate other complications with regard to sexual health, including low sexual desire, disturbed orgasmic function (i.e., anejaculation, orgasm intensity, painful orgasm, and climacturia), shortening of penile length, penile curvature (Peyronie's disease) and unique psychological alterations after the diagnosis of PCa, which are neglected side effects after prostatectomy. In this context, routine evaluation of erectile function by the International Index of Erectile Function only is not sufficient to understand patients' difficulties. A questionnaire is just one way of enabling patients to evaluate their pre‐ and postoperative concerns; listening to patients face‐to‐face is warranted to detect symptoms. Understanding the relationship between symptoms and preserved nerve localization can ultimately provide an individualized nerve‐sparing procedure and improve patient satisfaction after RARP. In combination with psychological counseling, including the partner and medical treatment, such as testosterone replacement, it is time to reconsider ways to improve sexual dysfunction after RARP.

show abstract

Section: Psychological Concernsmentioning

confidence: 99%

Section: Psychological Concernsmentioning

confidence: 99%

Evaluation of sexual function after robot‐assisted radical prostatectomy: A farewell toIIEFquestionnaire

Shiraishi

2023

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…Of men undergoing PC therapy, 72% to 92% experience diminished sexual health that is likely to persist after successful completion of treatment 59 . Following definitive therapy, patients may experience erectile dysfunction, climacturia, penile shortening, altered orgasms and loss of libido, which can significantly impact their intimate relationships 60 .…”

Section: Role Of the Nurse Specialist In Managing Adverse Drug Eventsmentioning

confidence: 99%

New treatments for patients with non‐metastatic castration‐resistant prostate cancer: A nursing perspective

Olivier

Floyd

Smith

et al. 2021

Int J of Uro Nursing

View full text Add to dashboard Cite

Globally, prostate cancer (PC) is a leading cause of death in men. Although androgen deprivation therapy (ADT) is the cornerstone of treatment for the disease, most patients eventually develop castration‐resistant PC (CRPC). Patients with non‐metastatic (nm) CRPC, the earliest clinical manifestation of castration resistance, are at risk of progressing to metastatic CRPC, which is associated with reduced life expectancy and poor quality of life. The nmCRPC treatment landscape has recently been transformed by the approval of three next‐generation oral androgen receptor (AR) inhibitors: apalutamide, enzalutamide and darolutamide. This review addresses available new treatment options for nmCRPC that target the AR, considering the effects of adverse event (AE) profiles and drug‐drug interactions (DDIs) when tailoring patient‐centric treatment to individual need, and discussing management strategies and nursing interventions for patients who experience drug‐related AEs. While no head‐to‐head comparisons of apalutamide, enzalutamide and darolutamide have been conducted to date, all three drugs have demonstrated comparable efficacy and maintained quality of life in phase III clinical trials, with differing AE profiles. The three treatments also demonstrate different potential for DDIs with other common medications that may be taken simultaneously. With the availability of new AR‐targeted options for nmCRPC, oncology nurses play a crucial role in the decision‐making process, educating and supporting patients on managing their PC, and ensuring that they receive the most appropriate treatment. As patients with nmCRPC are largely asymptomatic from their disease (with the exception of urinary/erectile symptoms), maintaining quality of life becomes a major objective when prescribing pharmacotherapy. Therefore, weighing treatment efficacy against the respective drug safety profile and examining the potential for adverse drug interactions with concomitant medications are important clinical considerations. Oncology nurses educate patients on potential treatment‐emergent AEs and their management and serve as advocates to ensure that patients receive optimal care based on their individual therapeutic requirements. They also provide information on available auxiliary services for patients and caregivers. This article provides an overview for the oncology nurse of the efficacy, safety, quality of life and DDI potential of these new AR‐targeted therapies in the nmCRPC setting, highlighting considerations for tailoring patient‐centric treatment to individual need. The importance of the oncology nurse in managing adverse drug reactions associated with ADT and AR inhibitors is highlighted and recommendations provided.

show abstract

“…2,3 Sexual dysfunction, the inability to achieve or maintain sexual activity due to less sexual desire or erectile dysfunction (ED), is one of the concerning adverse effects of radical therapies for prostate cancer. [4][5][6] Studies have shown that men on AS have lower risk of sexual dysfunction (and are more often sexually active) than men who undergo surgery/local therapy. [5][6][7][8] Preserving sexual function is one of the major reasons that patients delay treatment.…”

Section: Introductionmentioning

confidence: 99%

Factors impacting on sexual function among men on active surveillance for prostate cancer

et al. 2023

View full text Add to dashboard Cite

Background: Active surveillance (AS) aims to reduce overtreatment and minimize the negative side effects of radical therapies (i.e., prostatectomy or radiotherapy) while preserving quality of life. However, a substantial proportion of men can experience a decline in sexual function during AS follow-up. The aim of this study was to identify predictors of declining sexual function among men on AS. Methods: Men enrolled from 2008 to 2018 in the South Australian Prostate Cancer Clinical Outcomes Collaborative registry-a prospective clinical registry-were studied. Sexual function outcomes were measured using expanded prostate cancer index composite (EPIC-26) at baseline and 12-months postdiagnosis. Multivariable regression models adjusted for baseline score and other sociodemographic and clinical factors were applied to identify predictors of sexual function score at 12-months. Results: A total of 554 men were included. Variables that showed significant association with decline in sexual function score at 12-months were: having two or more biopsies after diagnosis (mean change score (MCS): -16.3, p < 0.001) compared with no biopsy, higher number of positive biopsy cores (MCS: -1.6, p = 0.004), being in older age category (above 70 vs. below 60: MCS: -16.7, p < 0.001; 65−70 vs. below 60: MCS: -9.7, p = 0.024), having had depression (MCS: -9.0, p = 0.020), and impaired physical function (MCS: -10.0, p = 0.031). Greater socioeconomic advantage (highest vs. lowest quintile: MCS: 15.7, p = 0.022) and year of diagnosis (MCS: 2.6 for every year, p < 0.001) were positively associated with 12-months sexual function score. Neither biopsy type, biopsy timing nor PSA velocity were associated with declines in sexual function. Conclusions: Our findings suggest that multiple factors affected sexual function during AS. Interventions toward reducing the number of biopsies through less invasive monitory approaches, screening for physical and mental well-being, and targeted emotional support and counseling services may be helpful for men on AS.

show abstract

Scandinavian Prostate Cancer Patients’ Sexual Problems and Satisfaction With Their Sex Life Following Anti-Cancer Treatment

Cited by 20 publications

References 41 publications

Evaluation of sexual function after robot‐assisted radical prostatectomy: A farewell toIIEFquestionnaire

Evaluation of sexual function after robot‐assisted radical prostatectomy: A farewell toIIEFquestionnaire

New treatments for patients with non‐metastatic castration‐resistant prostate cancer: A nursing perspective

Factors impacting on sexual function among men on active surveillance for prostate cancer

Contact Info

Product

Resources

About